Long-Term Clinical and Biological Prognostic Factors of Anti-NMDA Receptor Encephalitis in Children
Authors:
- Maxime MazowieckiMMMaxime Mazowiecki
- Lorraine Flet-BerliacLFLorraine Flet-Berliac
- Julia RouxJRJulia Roux
- Pascale ChretienPCPascale Chretien
- Salima Hacein-Bey-AbinaSHSalima Hacein-Bey-Abina
- Frederic VillegaFVFrederic Villega
- Emmanuel CheuretECEmmanuel Cheuret
- Marie BenaiteauMBMarie Benaiteau
- Veronique RogemondVRVeronique Rogemond
- Geraldine PicardGPGeraldine Picard
Open Access
- 1 March 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (2) , e200346
Abstract
Anti-NMDAR encephalitis (NMDARE) is a severe neurologic condition, and recently, the NMDAR Encephalitis One-Year Functional Status (NEOS) score has emerged as a 1-year prognostic tool. This study aimed to evaluate NEOS score and biomarker (neurofilament light chains [NfL], total-Tau protein, glial fibrillary acidic protein, and serum cytokines) correlation with modified Rankin Scale (mRS), cognitive impairment, and clinical recovery in pediatric NMDARE over 2 years. In this French multicenter observational study, 104 pediatric patients with NMDARE were followed for a minimum of 2 years. Clinical data and serum/plasma samples were collected. Biomarker levels, measured using electroluminescence mesoscale discovery (MSD) S-PLEX, were compared between patients and controls and assessed for correlations with disease activity, mRS, cognitive/language impairment, and recovery status at 2 years. At a median follow-up of 39.5 months, 68 percent of patients had unfavorable recovery and 54% had significant cognitive impairment. Both outcomes were strongly associated with younger age at diagnosis (OR 6.10 [1.91-27.3] p < 0.01 and 5.69 [1.46-27.7] p = 0.02, respectively). A higher NEOS score was significantly correlated with increased cognitive impairment (OR 2.53 [1.52-4.21], p < 0.001), higher mRS scores (OR 2.12 [1.34-3.57], p < 0.01), and unfavorable recovery at 2 years (OR 2.00 [1.30-3.06], p = 0.015). Elevated NfL levels were significantly associated with unfavorable recovery (OR 3.62 [1.29-10.9] p = 0.012) and severe cognitive impairment (OR 3.77 [1.38-10.9] p = 0.012) at 2 years. The combined area under the curve (AUC) for NfL and NEOS was significantly higher than the AUCs of NEOS and NfL alone (p = 0.01). The NEOS score strongly predicts long-term outcomes in NMDARE, with its predictive value extending beyond the first-year mR prediction. NfL levels at disease onset seem to improve accuracy in predicting poor outcomes, providing valuable information for treatment decisions and future clinical trials.Keywords
This publication has 28 references indexed in Scilit:
- Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation studyThe Lancet Neurology, 2023
- Modulation of astrocyte activity and improvement of oxidative stress through blockage of NO/NMDAR pathway improve posttraumatic stress disorder (PTSD)‐like behavior induced by social isolation stressBrain and Behavior, 2022
- Serum NfL associated with anti-NMDA receptor encephalitisNeurological Sciences, 2022
- Confounding effect of blood volume and body mass index on blood neurofilament light chain levelsAnnals of Clinical and Translational Neurology, 2020
- An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and modelsThe Lancet Neurology, 2019
- Cytokine/chemokine elevation during the transition phase from HSV encephalitis to autoimmune anti-NMDA receptor encephalitisBrain and Development, 2018
- A clinical approach to diagnosis of autoimmune encephalitisThe Lancet Neurology, 2016
- Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective studyThe Lancet Neurology, 2014
- Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort studyThe Lancet Neurology, 2013
- Anti–N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis in children and adolescentsAnnals of Neurology, 2009